CELLECTIS S.A.

In News

Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

MarketBeat - Jul 17, 2026

ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView

TradingView - Jul 16, 2026

What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings - Yahoo Finance

Yahoo Finance - Mar 19, 2026

[6-K] Cellectis S.A. Current Report (Foreign Issuer) | CLLS SEC Filing - Form 6-K - Stock Titan

Stock Titan - Jun 25, 2026

Cellectis Bets on Non-Viral Editing for Therapy Gains - CRISPR Medicine News

CRISPR Medicine News - Jan 28, 2026

Cellectis stock rises on FDA therapy designation - Investing.com

Investing.com - Jun 10, 2026

AstraZeneca, Cellectis targeted in patent lawsuit over gene-editing technology - Reuters

Reuters - Sep 26, 2025

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - marketscreener.com

marketscreener.com - Jun 25, 2026

Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com

Barchart.com - Jul 07, 2026

Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy - GuruFocus

GuruFocus - Jun 09, 2026

Price to book forward of Cellectis S.A. – EURONEXT:ALCLS - TradingView

TradingView - Jul 05, 2026

Shareholders of Cellectis (NASDAQ: CLLS) reject savings plan issue - Stock Titan

Stock Titan - Jun 26, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment